Unknown

Dataset Information

0

A Liposome Encapsulated Ruthenium Polypyridine Complex as a Theranostic Platform for Triple-Negative Breast Cancer.

ABSTRACT: Ruthenium coordination complexes have the potential to serve as novel theranostic agents for cancer. However, a major limitation in their clinical implementation is effective tumor accumulation. In this study, we have developed a liposome-based theranostic nanodelivery system for [Ru(phen)2dppz](ClO4)2 (Lipo-Ru). This ruthenium polypyridine complex emits a strong fluorescent signal when incorporated in the hydrophobic lipid bilayer of the delivery vehicle or in the DNA helix, enabling visualization of the therapeutic agent in tumor tissues. Incubation of MDA-MB-231 breast cancer cells with Lipo-Ru induced double-strand DNA breaks and triggers apoptosis. In a mouse model of triple-negative breast cancer, treatment with Lipo-Ru dramatically reduced tumor growth. Biodistribution studies of Lipo-Ru revealed that more than 20% of the injected dose accumulated in the tumor. These results suggest that Lipo-Ru could serve as a promising theranostic platform for cancer.

SUBMITTER: Shen J 

PROVIDER: S-EPMC5484597 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

A Liposome Encapsulated Ruthenium Polypyridine Complex as a Theranostic Platform for Triple-Negative Breast Cancer.

Shen Jianliang J   Kim Han-Cheon HC   Wolfram Joy J   Mu Chaofeng C   Zhang Wei W   Liu Haoran H   Xie Yan Y   Mai Junhua J   Zhang Hang H   Li Zhi Z   Guevara Maria M   Mao Zong-Wan ZW   Shen Haifa H  

Nano letters 20170421 5

Ruthenium coordination complexes have the potential to serve as novel theranostic agents for cancer. However, a major limitation in their clinical implementation is effective tumor accumulation. In this study, we have developed a liposome-based theranostic nanodelivery system for [Ru(phen)<sub>2</sub>dppz](ClO<sub>4</sub>)<sub>2</sub> (Lipo-Ru). This ruthenium polypyridine complex emits a strong fluorescent signal when incorporated in the hydrophobic lipid bilayer of the delivery vehicle or in t  ...[more]

Similar Datasets

Unknown Nucleus-enriched Ruthenium Polypyridine Complex Acts as a Potent Inhibitor to Suppress Triple-negative Breast Cancer Metastasis In vivo.
| S-EPMC6297906 | biostudies-literature
Unknown The LINC01119-SOCS5 axis as a critical theranostic in triple-negative breast cancer.
| S-EPMC8166834 | biostudies-literature
Unknown Encapsulated Rose Bengal Enhances the Photodynamic Treatment of Triple-Negative Breast Cancer Cells.
| S-EPMC10820979 | biostudies-literature
Unknown Triple Negative Breast Cancer Preclinical Therapeutic Management by a Cationic Ruthenium-Based Nucleolipid Nanosystem.
| S-EPMC10094725 | biostudies-literature
Unknown Cytotoxicity and anti-tumor effects of new ruthenium complexes on triple negative breast cancer cells.
| S-EPMC5595280 | biostudies-literature
Unknown Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine.
| S-EPMC3783505 | biostudies-literature
Unknown Quantum-Dot-Based Theranostic Micelles Conjugated with an Anti-EGFR Nanobody for Triple-Negative Breast Cancer Therapy.
| S-EPMC5918284 | biostudies-literature
Unknown A fast ruthenium polypyridine cage complex photoreleases glutamate with visible or IR light in one and two photon regimes.
| S-EPMC2835317 | biostudies-literature
Unknown Biotinylated Polymer-Ruthenium Conjugates: In Vitro and In Vivo Studies in a Triple-Negative Breast Cancer Model.
| S-EPMC9315599 | biostudies-literature
Unknown Triple-negative breast cancer.
| S-EPMC2972557 | biostudies-literature